Abstract
We conducted an open label, randomised clinical trial to compare amphotericin B colloidal dispersion (ABCD, Amphocil) 2 mg/kg/day intravenously with fluconazole 200 mg/day orally, for the prevention of fungal disease in neutropenic patients with haematological malignancies. In the event of unresolved fever after 4 days of empirical antibacterial therapy, patients in both treatment groups were to receive ABCD, 4 mg/kg/day. However, the study had to be stopped in an early phase, due to severe side-effects of ABCD. A total of 24 patients were enrolled, 12 patients were randomly assigned to receive prophylactic ABCD, which was administered for a mean of 13.9 days. Fluconazole prophylaxis was given to 12 patients for a mean of 21.2 days. Therapeutic ABCD, 4 mg/kg, was initiated in four patients because of suspected fungal infection, all of whom had initially received fluconazole. A high rate of infusion-related toxicity of ABCD was observed. Chills occurred in 15/16 ABCD recipients (94%), accompanied by a temperature rise of ⩾2°C in 4/16 patients and of ⩾1°C but <2°c in 10/16 patients. Other abcd-related adverse events were hypotension (4/16), nausea with vomiting (5/16), tachycardia (7/16), headache (3/16) and dyspnoea (3/16). For premedication patients received: antihistamines (12/16), hydrocortisone (9/16) and/or morphine (6/16). ABCD was discontinued in 8/16 patients (50%) due to side-effects, which ultimately dictated early termination of the study. we conclude that ABCD is not suitable for antifungal prophylaxis in neutropenic patients due to severe infusion-related side-effects. Subject numbers were too low for conclusions on variables of antifungal efficacy. Bone Marrow Transplantation(2000) 25 , 879–884.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Walsh TJ, Hiemenz JW, Anaissie E . Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients Infect Dis Clin N Am 1996 10: 365–400
DeGregorio MW, Lee WM, Linker CA et al. Fungal infections in patients with acute leukemia Am J Med 1982 73: 543–548
Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey Eur J Clin Microbiol Infect Dis 1992 11: 99–109
Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation New Engl J Med 1992 326: 845–851
Huijgens PC, van Loenen AC, Simoons-Smit AM et al. The prophylactic use of fluconazole 50 vs 100mg daily in haematological malignancies Eur J Cancer 1993 29A: 926–927
Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y . Antifungal prophylaxis with low-dose fluconazole during bone marrow transplanation. The Bone Marrow Transplantation Team Bone Marrow Transplant 1994 14: 919–924
Menichetti F, Del Favero A, Martino P et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program Ann Intern Med 1994 120: 913–918
Schaffner A, Schaffner M . Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias J Infect Dis 1995 172: 1035–1041
Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomised, double-blind study J Infect Dis 1995 171: 1545–1552
Huijgens PC, Simoons-Smit AM, van Loenen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology J Clin Pathol 1999 52: 376–380
Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial Ann Intern Med 1993 118: 495–503
Perfect JR, Klotman ME, Gilbert CC et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients J Infect Dis 1992 165: 891–897
Rousey SR, Russler S, Gottlieb M, Ash RC . Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation Am J Med 1991 91: 484–492
Riley DK, Pavia AT, Beatty PG et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients Am J Med 1994 97: 509–514
Bowden RA, Cays M, Gooley T et al. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant J Infect Dis 1996 173: 1208–1215
Herbrecht R . Safety of amphotericin B colloidal dispersion Eur J Clin Microbiol Infect Dis 1997 16: 74–80
Oppenheim BA, Herbrecht R, Kusne S . The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses Clin Infect Dis 1995 21: 1145–1153
Anaissie EJ, Mattiuzzi GN, Miller CB et al. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion Antimicrob Agents Chemother 1998 42: 606–611
Noskin G, Pietrelli L, Gurwith M, Bowden R . Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients Bone Marrow Transplant 1999 23: 697–703
Tollemar J, Ringden O, Andersson S et al. Randomised double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients Bone Marrow Transplant 1993 12: 577–582
Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study Bone Marrow Transplant 1999 23: 163–168
Arning M, Heer-Sonderhoff AH, Wehmeier A, Schneider W . Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia Eur J Clin Microbiol Infect Dis 1995 14: 41–43
Ringden O, Andstrom E, Remberger M et al. Allergic reactions and other rare side-effects of liposomal amphotericin Lancet 1994 344: 1156 (letter)
White MH, Bowden RA, Sandler ES et al. Randomised, double blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia Clin Infect Dis 1998 27: 296–302
Mehta J . Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leukemia Res 1997 21: 183–188
Leenders AC, de Marie S . The use of lipid formulations of amphotericin B for systemic fungal infections Leukemia 1996 10: 1570–1575
Ringden O, Jonsson V, Hansen M et al. Severe and common side-effects of Amphotericin B lipid complex (Abelcet) Bone Marrow Transplant 1998 22: 733 (letter)
Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A . Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels Mycoses 1995 38: 459–465
Chia JK, McManus EJ . In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations Antimicrob Agents Chemother 1990 34: 906–908
Acknowledgements
This study was supported by a grant from Zeneca Farma, Ridderkerk, The Netherlands, distributor of Amphocil for Europe.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Timmers, G., Zweegman, S., Simoons-Smit, A. et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 25, 879–884 (2000). https://doi.org/10.1038/sj.bmt.1702243
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702243
Keywords
This article is cited by
-
Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections
Infectious Diseases and Therapy (2021)
-
Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B
BMC Infectious Diseases (2015)
-
Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity
Drugs (2013)
-
Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials
British Journal of Cancer (2012)
-
Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections
Infection (2008)